NxStage Medical, Inc. (NXTM) Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC decreased its position in NxStage Medical, Inc. (NASDAQ:NXTM) by 66.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 84,783 shares of the medical device company’s stock after selling 166,200 shares during the period. Renaissance Technologies LLC owned approximately 0.13% of NxStage Medical worth $2,222,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Marshall Wace LLP bought a new stake in shares of NxStage Medical during the fourth quarter valued at approximately $5,976,000. Columbus Circle Investors increased its stake in shares of NxStage Medical by 75.6% in the third quarter. Columbus Circle Investors now owns 370,022 shares of the medical device company’s stock valued at $9,247,000 after buying an additional 159,355 shares during the period. BlackRock Institutional Trust Company N.A. increased its stake in shares of NxStage Medical by 10.5% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 1,660,469 shares of the medical device company’s stock valued at $41,495,000 after buying an additional 157,459 shares during the period. Advisory Research Inc. bought a new stake in shares of NxStage Medical during the fourth quarter valued at approximately $2,931,000. Finally, BlackRock Advisors LLC increased its stake in shares of NxStage Medical by 191.7% in the third quarter. BlackRock Advisors LLC now owns 168,822 shares of the medical device company’s stock valued at $4,219,000 after buying an additional 110,952 shares during the period. 97.26% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for NxStage Medical (NASDAQ:NXTM)

NxStage Medical, Inc. (NASDAQ:NXTM) traded down 1.715% during trading on Wednesday, hitting $21.495. The stock had a trading volume of 379,264 shares. NxStage Medical, Inc. has a 1-year low of $16.42 and a 1-year high of $30.80. The stock’s 50-day moving average price is $26.64 and its 200-day moving average price is $26.60. The company’s market capitalization is $1.41 billion.

NxStage Medical (NASDAQ:NXTM) last issued its earnings results on Tuesday, May 9th. The medical device company reported ($0.02) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.03) by $0.01. NxStage Medical had a negative net margin of 1.61% and a negative return on equity of 2.97%. The firm had revenue of $96.83 million during the quarter, compared to analysts’ expectations of $95.31 million. During the same quarter last year, the company posted ($0.02) earnings per share. The firm’s revenue was up 8.5% compared to the same quarter last year. Analysts expect that NxStage Medical, Inc. will post ($0.03) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “NxStage Medical, Inc. (NXTM) Shares Sold by Renaissance Technologies LLC” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://www.com-unik.info/2017/05/17/nxstage-medical-inc-nxtm-position-lowered-by-renaissance-technologies-llc-updated-updated-updated.html.

NXTM has been the subject of several analyst reports. Canaccord Genuity set a $31.00 price objective on NxStage Medical and gave the stock a “buy” rating in a research note on Monday, January 23rd. Jefferies Group LLC increased their price objective on NxStage Medical to $38.00 and gave the stock a “buy” rating in a research note on Monday, February 6th. Northland Securities reissued a “buy” rating and issued a $35.00 price objective on shares of NxStage Medical in a research note on Monday, April 3rd. Finally, BTIG Research reissued a “buy” rating and issued a $27.00 price objective on shares of NxStage Medical in a research note on Wednesday, May 10th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $28.67.

In related news, Director Craig W. Moore sold 1,000 shares of the firm’s stock in a transaction on Thursday, March 16th. The shares were sold at an average price of $27.93, for a total transaction of $27,930.00. Following the sale, the director now owns 94,943 shares in the company, valued at $2,651,757.99. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Winifred L. Swan sold 3,500 shares of the firm’s stock in a transaction on Monday, May 15th. The shares were sold at an average price of $21.94, for a total transaction of $76,790.00. Following the sale, the senior vice president now owns 17,770 shares in the company, valued at approximately $389,873.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 101,560 shares of company stock valued at $2,803,364. 4.70% of the stock is currently owned by corporate insiders.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

5 Day Chart for NASDAQ:NXTM

What are top analysts saying about NxStage Medical Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NxStage Medical Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit